Please use this identifier to cite or link to this item:
Title: Modification of the association between frequent aspirin use and ovarian cancer risk: A meta-analysis using individual-level data from two ovarian cancer consortia.
Author: Hurwitz, L.
Townsend, M.
Jordan, S.
Patel, A.
Teras, L.
Lacey, J.
Doherty, J.
Harris, H.
Goodman, M.
Shvetsov, Y.
Modugno, F.
Moysich, K.
Robien, K.
Prizment, A.
Schildkraut, J.
Berchuck, A.
Fortner, R.
Chan, A.
Wentzensen, N.
Hartge, P.
Sandler, D.
O'Brien, K.
Anton-Culver, H.
Ziogas, A.
Menon, U.
Ramus, S.
Pearce, C.
Wu, A.
White, E.
Peters, U.
Webb, P.
Tworoger, S.
Trabert, B.
Issue Date: 2023
Publication Title: Journal of Clinical Oncology
Volume: 40
Issue: 36
Start Page: 4207
End Page: 4217
Abstract: Purpose: Frequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association between frequent aspirin use and ovarian cancer risk, overall and across subgroups of women with other ovarian cancer risk factors. Methods: Nine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included. We used Cox regression and logistic regression to assess study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk and combined study-specific estimates using random-effects meta-analysis. We conducted analyses within subgroups defined by individual ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) and by number of risk factors (0, 1, and ≥ 2). Results: Overall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (95% CI, 6 to 20), with no significant heterogeneity by study design (P = .48) or histotype (P = .60). Although no association was observed among women with endometriosis, consistent risk reductions were observed among all other subgroups defined by ovarian cancer risk factors (relative risks ranging from 0.79 to 0.93, all P-heterogeneity > .05), including women with ≥ 2 risk factors (relative risk, 0.81; 95% CI, 0.73 to 0.90). Conclusion: This study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors. Risk reductions were also observed among women with multiple risk factors, providing proof of principle that chemoprevention programs with frequent aspirin use could target higher-risk subgroups.
Description: Includes data from BHS
Internal ID Number: 02052
Health Subject: ASPIRIN
Type: Journal Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.